ArticleAdvanced biomedical research2025
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges.International journal of molecular sciences · 2026Pooled it
- Nanoparticle-Based Radiosensitization in Breast Cancer: A Multimodal Approach to Therapy and Immune Regulation.Biotechnology journal · 2026Review
- Emerging nanocarriers designed for the enhanced delivery of doxorubicin.Nanomedicine (London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is one of the major causes of cancer death in women. Usually, surgery, chemotherapy, and radiotherapy are commonly used in the treatment of breast cancer, but these methods have significant side effects and low survival rates. By developing combination therapies, side effects can be reduced so that therapeutic efficacy is maintained. The aim of this study was to examine the effects of radiotherapy combined with chemotherapy using combined gem and gold nanoparticle for the treatment of breast cancer. Materials and Methods: In this study, PEGylated gold nanoparticles (PEG-GNPs) were synthesized and loaded with an anticancer agent, gemcitabine (Gem-PEG-GNPs). Then, GNPs, PEG-GNPs, and Gem-PEG-GNPs were investigated using several techniques, including UV-Vis, FTIR, DLS, and TEM analysis. After that, the efficacy of the synthesized nanoparticles for chemoradiotherapy was evaluated through Results: The prepared Gem-PEG-GNPs act as radiosensitizers and nanocarrier, which increases the effectiveness of radio chemotherapy and reduces side effects. Combining Gem-PEG-GNPs with X-ray irradiation increased apoptosis and decreased survival rates of MCF-7 cells. When Gem-PEG-GNPs and radiation were combined, a significant synergistic effect was observed compared to the effect of radiation alone. Conclusion: Gem-PEG-GNPs can have the potential of an effective and radiosensitizing drug delivery agent against breast cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.